[HTML][HTML] Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model
S Grossauer, K Koeck, NE Murphy, ID Meyers… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Abstract Inhibitors of BRAF V600E kinase are currently under investigations in preclinical
and clinical studies involving BRAF V600E glioma. Studies demonstrated clinical response …
and clinical studies involving BRAF V600E glioma. Studies demonstrated clinical response …
Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas
J Zhang, TW Yao, R Hashizume, S Hariono… - Journal of Neuro …, 2017 - Springer
Abstract BRAF V600E is a common finding in glioma (about 10–60% depending on
histopathologic subclassification). BRAF V600E monotherapy shows modest preclinical …
histopathologic subclassification). BRAF V600E monotherapy shows modest preclinical …
[HTML][HTML] Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases
PYM Woo, TC Lam, JKS Pu, LF Li, RCY Leung… - Oncotarget, 2019 - ncbi.nlm.nih.gov
Background Up to 15% of young adults with glioblastoma have the activating oncogenic
BRAF V600E mutation, an actionable target of the MAPK signal transduction pathway …
BRAF V600E mutation, an actionable target of the MAPK signal transduction pathway …
BRAF status in personalizing treatment approaches for pediatric gliomas
A Olow, S Mueller, X Yang, R Hashizume… - Clinical Cancer …, 2016 - AACR
Purpose: Alteration of the BRAF/MEK/MAPK pathway is the hallmark of pediatric low-grade
gliomas (PLGGs), and mTOR activation has been documented in the majority of these …
gliomas (PLGGs), and mTOR activation has been documented in the majority of these …
[HTML][HTML] EGFR blockade prevents glioma escape from BRAFV600E targeted therapy
Mutational activation of BRAF (BRAF V600E) occurs in pediatric glioma and drives aberrant
MAPK signaling independently of upstream cues. Targeted monotherapy against BRAF …
MAPK signaling independently of upstream cues. Targeted monotherapy against BRAF …
[HTML][HTML] Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas
Activating mutation of BRAF is a common finding in pediatric gliomas. As many as 14% of
high grade and up to 66% of certain subtypes of low grade pediatric glioma have the BRAF …
high grade and up to 66% of certain subtypes of low grade pediatric glioma have the BRAF …
PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma
MM Deuker, V Marsh Durban, WA Phillips, M McMahon - Cancer discovery, 2015 - AACR
Abstract Phosphatidylinositide 3′(PI3′)-lipid signaling cooperates with oncogenic
BRAFV600E to promote melanomagenesis. Sustained PI3′-lipid production commonly …
BRAFV600E to promote melanomagenesis. Sustained PI3′-lipid production commonly …
[HTML][HTML] Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
The identification of BRAF V600 mutation in multiple cancers beyond melanoma and the
development of combined BRAF and MEK targeting agents have altered the landscape of …
development of combined BRAF and MEK targeting agents have altered the landscape of …
[HTML][HTML] Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAFV600E-mutant melanoma
AL Harris, SE Lee, LK Dawson, LA Marlow… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Patient-derived tumor xenograft (PDTX) mouse models were used to discover new therapies
for naïve and drug resistant BRAF V600E-mutant melanoma. Tumor histology, oncogenic …
for naïve and drug resistant BRAF V600E-mutant melanoma. Tumor histology, oncogenic …
[HTML][HTML] BRAFV600E kinase domain duplication identified in therapy-refractory melanoma patient-derived xenografts
K Kemper, O Krijgsman, X Kong… - Cell reports, 2016 - cell.com
The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show
promising results, but drug resistance often limits durable clinical responses. There is a …
promising results, but drug resistance often limits durable clinical responses. There is a …